Lv1
40 积分 2024-05-27 加入
Response and Resistance to RAS Inhibition in Cancer
6小时前
已完结
The evolving landscape of RAS-targeted therapies
6小时前
已完结
Management of obesity
6天前
已完结
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
10天前
已完结
Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome
11天前
已完结
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
20天前
已完结
Pre-Enrollment Steps and Run-Ins in Weight Loss Trials: A Meta-Regression
22天前
已关闭
Chimeric antigen receptor-engineered (CAR)-T cell therapy for metastatic prostate cancer
28天前
已完结
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
1个月前
已关闭
Darinaparsin: First Approval
1个月前
已完结
皖公网安备34019202002308
